Table 2.
Effects of calcitriol on patients with type 1 diabetes
| Calcitriol group | Control group | |||
|---|---|---|---|---|
|
|
|
|||
| Baseline | Month 6 | Baseline | Month 6 | |
| Age (y) | 23.95 ± 5.21 | 24.86 ± 7.01 | ||
| Sex (male/female) | 11/10 | 4/3 | ||
| Duration (y) | 9.81 ± 3.25 | 7.86 ± 4.26 | ||
| ACEI/ARB | 6/15 | 2/5 | ||
| SBP (mmHg) | 107.1 ± 10.63 | 104.71 ± 9.83* | 105.71 ± 10.23 | 104.57 ± 6.8 |
| DBP (mmHg) | 68.9 ± 6.07 | 67.14 ± 5.85* | 67.14 ± 5.61 | 66.86 ± 2.97 |
| HbA1C (%) | 7.88 ± 0.58 | 7.1 ± 0.5 | 7.71 ± 0.69 | 7.31 ± 0.4 |
| AUCC-peptide (nmol/L × 120 min) | 35.94 ± 12.3 | 33.2 ± 9.6 | 34.67 ± 7.27 | 31.05 ± 6.6 |
| Daily insulin dose (u) | 24.19 ± 5.53 | 24.57 ± 6.32 | 26.57 ± 3.6 | 26.86 ± 4.74 |
| 25(OH)D3 (ng/ml) | 20.61 ± 4.29 | 27.16 ± 2.9* | 38.48 ± 4.4* | 37.16 ± 5.88 |
| PTH (pg/ml) | 42.82 ± 1.3 | 41.68 ± 0.98 | 39.21 ± 1.67 | 40.8 ± 1.17 |
| Calcium (mmol/l) | 2.17 ± 0.1 | 2.24 ± 0.11* | 2.28 ± 0.08* | 2.25 ± 0.08 |
| Phosphorus (mmol/l) | 1.22 ± 0.2 | 1.21 ± 0.18 | 1.28 ± 0.27 | 1.23 ± 0.11 |
| hsCRP (mg/L) | 1.34 ± 0.34 | 0.94 ± 0.22* | 1.03 ± 0.19* | 1.05 ± 0.18 |
| TNF-a (pg/ml) | 57.7 ± 10.7 | 47.09 ± 7.73* | 48.84 ± 5.03* | 50.07 ± 4.8 |
| IL-6 (pg/ml) | 44.04 ± 7.29 | 39.88 ± 7.86* | 37.3 ± 6.99* | 38.14 ± 8.01 |
| Urine MCP-1/creatinine (ng/mmol) | 99.38 ± 25.29 | 89.57 ± 21.46* | 89.43 ± 30.21 | 87.43 ± 22.59 |
| Urine TGF-b/creatinine (ng/mmol) | 79 ± 28.89 | 72.33 ± 25.61* | 74.43 ± 27.23 | 76.14 ± 25.47 |
| Urinary albumin excretion (μg/mg) | 127.05 ± 84.79 | 104.81 ± 74.05* | 101.96 ± 59.38 | 102.7 ± 59.8 |
*
P < 0.05 compared to baseline data of patients with calcitriol.